Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CryoLife takes haemostatic tech to Canada with Sorin

This article was originally published in Clinica

Executive Summary

Biomaterials and tissue processing company CryoLife is set to make its Hemostase MPH bleeding control agent available in Canada through the Canadian subsidiary of cardiovascular firm Sorin. Hemostase uses microporous polysaccharide hemospheres technology (MPH), which CryoLife says produces a plant-based powder that rapidly dehydrates blood and enhances clotting. According to the firm, pre-clinical trials show that Hemostase “does not promote infection and absorbs with 24-48 hours of application at the wound site, compared to other surgical haemostats which can take 3-8 weeks or more to fully break down”. CryoLife (Atlanta, Georgia) began distributing Hemostase in the US, UK and Germany in the second quarter of 2008 and expects to expand into other geographical markets this year and the next. Financial details of the deal with Sorin were not disclosed.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT042209

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel